Whether working in the pharmaceutical industry or in academia or government, the skills required to achieve, maintain and grow a career are vastly different today than they were 30 years ago. A session at DIA 2021 will put the spotlight on the skills...
A representative from Thermo Fisher Scientific addresses how bringing research and resources directly to participants can address problems with studies.
Thanks in part to swift COVID-19 response and relatively low infection rates, more sites and sponsors are looking at the region to locate their studies.
In partnership with 23andMe, the group has released a wealth of new de-identified data from the largest-ever Parkinson’s cohort, to aid future research.
The US agency’s latest actions and advice against the virus include information on test recalls, , approval and reauthorization of treatments, and more.
Dutch biotech, Byondis, today announced positive topline results from a Phase 3 study, which it says confirms the safety and efficacy of its antibody drug conjugate (ADC) - SYD985 - as a treatment for patients with pretreated HER2-positive locally advanced...
The virtual clinical development firm’s analysis of patient profiles reflects obesity is the most significant indicator for severity in those under 40.
The US Food and Drug Administration (FDA) has approved Biogen’s Aduhelm (aducanumab) for the treatment of Alzheimer’s: making it the first new treatment approved for the disease since 2003.
The Digital Health Measurement Collaborative Community is bringing together stakeholders to improve approaches and technologies in research and healthcare.
The life-sciences data outfit has chosen former FDA principal deputy commissioner Amy Abernethy to serve as president of its clinical research business.
COVID-19 vaccination via Vaxxas’ novel high-density microarray patch showed 'significantly enhanced' T-cell and spike-specific antibody responses compared to needle delivery, according to a pre-print preclinical study published this week.
The University of Kansas Cancer Center has joined with trial tech provider Complion to develop a shared investigator platform for use in a range of studies.
The pharma firm plans to use the StudyTeam platform to accelerate development, ease site burdens and improve patient matching for breast cancer studies.
